does pfizer make glp 1 drugs 2 Companies Poised to Capitalize on the Rise of GLP-1 Weight Loss Pfizer discontinues oral GLP-1 receptor

GLP-1-targeted therapies have seen continuous updates over the past decades

The new Eli Lilly pill is orforglipron, an oral GLP-1 medication designed to support weight loss and improve blood sugar

While the exclusion of weight management treatment may limit reimbursement of GLP-1s, non-obesity/overweight diseases such as diabetes mellitus and certain cardiovascular conditions may be eligible for reimbursement because these indications are not excluded

The injectable GLP-1 medications currently on the market have published higher average weight loss figures in their landmark trials: Semaglutide (Wegovy): Demonstrated approximately 14.9% average body weight reduction in the STEP 1 trial

The clinical evidence behind it is not

GLP-1 & GIP: It retains the appetite suppression, gastric slowing, and insulin-boosting properties of Tirzepatide